Featured Posts
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…
City Journal
The FTC Jettisons Economics—and Law
The Federal Trade Commission is stepping up its pursuit of its new favorite bogeyman: Pharmacy Benefit Managers. Two months ago, the FTC issued an …
Search Posts
Blog
One Year Later, Federal Plan on Tobacco Harm Reduction Needs Improvement
The Food and Drug Administration has failed to approve a single reduced-harm nicotine product in the past year, despite unveiling a new “roadmap” in…
Blog
Growing Human Organs for Fun and Profit
Our friends at Freethink Media have an excellent new video out about medical innovation—in this case, how a new company is developing…
The Washington Examiner
Trump Keeps His Promise, Dying Patients Get a Second Chance At Life
The Washington Examiner cited the Competitive Enterprise Institute on the direct toll to human life that regulations impose as a result of ever-increasing FDA clinical…
The Hill
‘Right to Try’ Is a Win for Patient Rights and President Trump
The Hill cited the Competitive Enterprise Institute on the overwhelming cost of compliance which taxes the American economy and in this case limits pharmaceutical ingenuity…
Blog
Congress Could Give Desperate Patients ‘Right to Try’ Experimental Medications
The House of Representatives will soon vote on a companion bill to S. 204, the Right to Try Act. This bill would prevent the…
U.S. News & World Report
Don’t Blunt the Marijuana Revolution
U.S. News & World Report covers the coalition letter, led by CEI, advocating for the Rohrabacher medical marijuana amendment. America is undergoing a somewhat…